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Abstract 
Previous studies performed in our lab examining the influence of IL-15 on 
antigen-independent expansion and differentiation of human CD8+ T cells led to the 
finding that IL-15 was able to induce de novo expression of natural killer receptors 
(NKR) in purified CD8+CD56- T cells after 12 days in culture. NK-like CD8+ T cells 
induced by IL-15 displayed a regulatory (effector/memory) phenotype, and NKR 
upregulation was shown to be intrinsically related with CD56 acquisition. 
The major objective of this work was to establish optimal culture conditions in 
order to keep long-term cultures of CD8+ T lymphocytes, and study phenotypical 
features of the differentiated CD8+ T cells. 
To that end, CD8+ T cells were isolated from PBMC of healthy blood donors by 
magnetic purification and cultured in the continuous presence of IL-15 in combination 
with TCR-mediated stimuli given by the T-cell specific mitogen phytohaemagglutinin 
(PHA). Expression of the prototypic NK marker, CD56, was assessed by FACS every 
seven days, in combination with parameters of cell growth and survival. 
By combining IL-15 and PHA we were able to maintain CD8+ T lymphocytes in 
culture for long periods of time (up to 90 days). During this time, CD8+ T cells acquired 
a large granular morphology and a fraction of these cells, mostly blast cells, expressed 
the prototypic marker of NKT cells, CD56. Importantly, the establishment of long-term 
cultures of differentiating CD8+ T cells was only possible when IL-15 was combined 
every two weeks with PHA stimuli.  
These results suggest that the generation of highly differentiated CD8+ T cells is 
the result of the combination of TCR-dependent and TCR-independent signals. 
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Resumo 
Estudos prévios realizados no nosso laboratório avaliando a influência da IL-15 
na expansão e diferenciação antigénio-independente de células humanas T CD8+, 
demonstraram que esta citocina é capaz de induzir a expressão de novo de recetores 
natural killer (NKR) em linfócitos T CD8+CD56- purificados, após 12 dias de cultura. 
Células T CD8+ NK-like induzidas pela IL-15 apresentavam um fenótipo regulatório 
(efetor/memória) e a expressão aumentada de  NKR estava intrinsecamente relacionada 
com aquisição de CD56. 
O principal objetivo deste trabalho foi estabelecer condições de cultura ideais de 
modo a manter culturas de longo prazo de linfócitos T CD8+ e estudar caraterísticas 
fenotípicas destas células T CD8+ diferenciadas. 
Para esse fim, linfócitos T CD8+ foram isolados a partir de PBMC de dadores de 
sangue saudáveis por purificação magnética, e cultivados na presença contínua de IL-15 
em combinação com estímulos via TCR através do mitogénio específico para células T, 
fitohemaglutinina (PHA). A expressão do marcador prototípico de NK, CD56, foi 
avaliada por citometria de fluxo semanalmente, em combinação com parâmetros de 
crescimento celular e sobrevivência.  
Através da combinação de IL-15 e PHA conseguimos manter em cultura 
linfócitos T CD8+ por longos períodos de tempo (até 90 dias). Durante este período, as 
células T CD8+ adquiriram morfologia grande e granular, e uma fração destas células, 
sobretudo blastos, expressaram o marcador prototípico de células NKT, CD56. 
Particularmente, o estabelecimento de culturas a longo prazo de células T CD8+ 
diferenciadas só foi possível quando a IL-15 foi combinada cada duas semanas com o 
estímulo da PHA.  
Estes resultados sugerem o estabelecimento de linfócitos T CD8+ altamente 
diferenciados em resultado da combinação de sinais TCR-dependentes e TCR-
independentes. 
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I. Introduction 
1.1. Long-term cell cultures 
Human T cell lines and clones are useful tools to obtain information about the 
role of T cells in the immune response. Therefore, the development of methods to grow 
T cells in vitro in the mid 1970s was a major breakthrough for the study of these cells, 
providing important insight into the characterization of T cell subpopulations and the 
understanding of their functional roles [1]. 
By demonstrating the mitosis-inducing properties of the lectin 
phytohaemagglutinin (PHA) in 1960 [2],  Peter Nowel started the line of research that 
culminated with the discovery of interleukin-2 (IL-2), so-called T-cell growth factor [3, 
4]. For the first time, immunologists were able to grow ex vivo T-lymphocytes and 
obtain clones of cytotoxic T-cells, using IL-2 [3, 4]. 
Although some studies describing the effects of IL-2 on human T cells appeared 
between 1976 and 1980, [5], it was not before the beginning of the eighties that the first 
stable human T cell clones were reported [6-8]. 
 
1.1.1. Antigen-specific versus antigen independent cell culturing 
A large variety of protocols have been described for the in vitro expansion of T 
cells, and today it is possible to easily propagate T cells using conventional multi-well 
tissue culture plates or flasks [9]. 
In view of the presumed requirements for antigenic stimulation, a culture system 
was devised for the generation and expansion of stable allo-antigen-specific cloned 
human T-cell lines, with a feeder cell mixture, consisting of irradiated peripheral blood 
mononuclear cells (PBMC), an Epstein-Barr virus-transformed lymphoblastoid cell line 
(EBV-LCL), expressing the specific allo-antigen, and phytohemaglutinin, resulting in 
the amplification and enrichment of T cells directed against the stimulating 
antigen/peptide [1, 9]. Apparently, PHA can replace the requirement of antigen-
mediated triggering of the TCR for T-cell activation by inducing the expression of the 
IL-2 receptor α (IL-2Rα) chain (CD25) on the T-cells. [1, 10, 11]. 
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 Recent findings show that naïve CD8+ T cells of human and mouse origin can 
be stimulated by cytokines without requirement for a nominal antigen [12-15]. 
Cytokines clearly play an important role in allowing survival and proliferation of 
activated T cells, and it has been shown that cytokine-mediated signals can control 
lymphocyte proliferation by regulating the expression of cell cycle proteins that control 
entry into the S phase of the cell cycle [16]. 
 
1.1.2. Long-term antigen-independent CD8
+
 T cell culture 
Due to the aforementioned discovery of mitosis-induced properties of the lectin 
PHA and the discovery of the T-cell growth factor IL-2, several studies, reported the 
long-term antigen-independent successful culturing of CD8+ T cells using this 
combination, and it is worth mentioning that this methodology has been widely used to 
grow or expand T cells in vitro.  
In order to test the effects of replicative senescence in the ability of human T 
cells to undergo apoptosis, Spaulding et al. compared the same population of T cells at 
different stages of their in vitro replicative life span. An in vitro culture model of 
cellular aging was achieved by adding recombinant IL-2 and allogeneic irradiated EBV-
transformed B cells (that serve as APC), reaching up to 25 population doublings [17].   
A different study with the goal to analyse the mechanisms responsible for 
regulating CD28 expression in primary human CD8+ T lymphocytes subjected to 
chronic activation, produced cultures reaching 20 population doublings, using rIL-2 and 
restimulation with APCs (PBMC combined with EBV-transformed B lymphoblastoid 
cells) every 21-28 days [18].  
Valenzuela and Effros followed a series of long-term CD8+ enriched cultures for 
79 to 238 days, using a protocol involving the use of IL-2 and restimulation with APC 
every 14-25 days, to elucidate the long-term telomerase dynamics in human T-cells 
[19].  
In another study, an experimental approach was undertaken to compare the 
phenotypic changes of human CD8+ T lymphocytes occurring during in vivo ageing and 
during replicative senescence in vitro. Lymphocytes were cultured in vitro for 30 to 35 
days in the presence of IL-2, and with PHA adding at the time of seeding [20].   
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To assess the mechanisms that limit the in vitro proliferative potential of human 
CD8+ T lymphocytes, Migliaccio et al. cultured T cells for up to 95 days using IL-2, 
PHA and irradiated allogeneic PBMC as feeder cells. The restimulation procedure was 
repeated every 10 or 15 days [21].  
Finally, on a different study with the goal to investigate the effect of introducing 
an exogenous CD28 gene into cultures of chronically activated human CD8+ T cells, 
these cells were exposed to T cell activation microbeads (anti-CD2/3/28) and stimulated 
repeatedly every 14 days. Cultures were supplemented with IL-2 and survived after 
seventh restimulation [22]. 
More recently, cytokines such as IL-7 and IL-15 have raised considerable 
interest for their potent effect on activation and expansion of T cells. They therefore 
present a strong potential for the optimization of in vitro expansion, although their 
effects seem to vary according to the type of cells affected: IL-7 is crucial for naïve 
CD8+ T cells survival, whereas IL-15 exerts its effects on memory CD8+ T cells. [23, 
24]. 
A previous study by our group examined the influence of IL-15 on antigen-
independent expansion and differentiation of human CD8+ T cells. All human T-cell 
subsets, both naïve and primed human T cells, divided in response to IL-15, which 
suggests a generic influence of this cytokine on CD8+ T-cell survival and proliferation, 
opening the possibility for T-cell antigen-independent culturing with IL-15 [12]. 
In this context, it is important to note that most studies using IL-15 have focused 
on short-term T-cell cultures [25-27]. In order to examine functional differences 
between IL-2 and IL-15 in the regulation of T cell activation, Bulfone-Paus et al. 
stimulated human T lymphoblasts with IL-15 for 24 to 48 hours [25]. A similar 
experimental study was developed by Cornish et al., to assess the actions of IL-2 and 
IL-15 on protein synthesis and cell growth on antigen-activated T CD8+ T cells isolated 
from spleens and lymph nodes of transgenic mice. Cells were cultured for 10 days with 
IL-15 [26]. 
In a more recent study, the effect of exogenous IL-15 added every 4 days on the 
expansion of CD3+CD56+ NKT-like cells in vitro present on cord blood mononuclear 
cells was examined for up to 14 days [27]. 
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To this point, only a few studies have focused on long-term cultures of CD8+ T 
cells using IL-15 as a growth factor. Thus, in order to evaluate the role of IL-15 in the 
maintenance of antigen-specific CTL in culture and to determine whether these cells 
would retain their effector function, Lu et al. were able to culture CD8+ T lymphocytes 
lasting up to 80 days in culture with IL-15 adding every 2 or 3 days, and stimulation 
with anti-CD3 in the presence of irradiated feeder cells [28]. Subsequent studies by Li et 
al. used IL-15 stimulation every 10 days, with anti-CD3/CD28 stimulation at seeding, 
and were able to grow T CD8+ cells for 45 to 80 days, allowing the study of the role of 
IL-15 in regulating the replicative capacity of memory CD8+ T cells [29]. 
Studies involving long-term cultures with IL-15 addition are more common for 
NK cells. With the purpose of demonstrating the potential for IL-15 to support large-
scale expansion of clinical-grade LAK-NK effectors, Suck et al. expanded CD56+CD3- 
NK cells with IL-15 for up to 4 weeks [30]. More impressive was the study of Choi et 
al., in which the effects of IL-15 on neonatal NK cells was examined for up to 12 weeks 
in culture [31]. 
 
 
1.2. Interleukin-15 
Interleukin-15 is a pleiotropic cytokine that belongs to the 4-α-helix bundle 
cytokine family, which binds to receptors of the hematopoietin family [32, 33], along 
with cytokines such as IL-2, IL-3, IL-4, IL-6 and IL-21, but also growth factors like 
granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-
stimulating factor (G-CSF), erythropoietin and classical hormones, including human 
growth hormone and prolactin [34]. Not surprisingly, being a member of this very 
diverse family, IL-15 exerts its functions on the proliferation, survival and 
differentiation of many distinct cell types, hence its designation as pleiotropic [32, 35]. 
IL-15 was simultaneously discovered in 1994 by two independent research 
groups [36, 37], having its sudden interest aroused due to its structural similarities with 
IL-2.  
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1.2.1. IL-15 and its structural cousin IL-2 
A special feature of IL-15 is that it shares with IL-2 the IL-2 receptor beta (IL-
2Rβ) and IL-2 receptor gamma common (IL-2Rγc) chains [38-41], which are 
responsible for downstream cytoplasmic signals [33, 35]. IL-2 and IL-15 also associate 
with a unique third chain, IL-2Rα and IL-15Rα, respectively [38] (Figure 1.1).  
 
Figure 1.1. Representation of the IL-15 and IL-2 receptors. A special feature of IL-15 is that it shares 
with IL-2 the IL-2Rβ and IL-2Rγc chains which are responsible for downstream cytoplasmic signals. IL-2 
and IL-15 also associate with a unique third chain, IL-2Rα and IL-15Rα, respectively. Adapted from [35, 
42-44]. 
 
 
However, since these α-chains have short cytoplasmic domains, they do not 
appear to contribute directly to signal transduction. The primary role of these α chains 
appears to be to assist the formation of high-affinity receptor complexes conferring 
ligand specificity since each α-chain recognizes only it’s cognate cytokine [35], and to 
regulate the size and content of the peripheral lymphoid compartment [45]. In fact, in 
the absence of an α-chain, the IL-2Rβ-γc dimer can respond to either IL-2 or IL-15, 
although with lower affinity [45]. 
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Due to the sharing of receptor subunits by IL-2 and IL-15 some authors have 
proposed that these cytokines may have redundant functions [25]. In fact, they perform 
a similar spectrum of biological activities, mainly in three major lymphoid cell types: 
Ig-producing B cells, antigen-specific cytotoxic and helper T cells, and natural killer 
cells. However, a series of latter studies have shown that, despite their many 
overlapping functional properties, IL-2 and IL-15 are in fact markedly distinct players 
in the immune system [25]. While IL-2 is critical in the maintenance of peripheral 
homeostasis of thymus-derived T cells, IL-15 promotes extrathymic T and NK cell 
development hence serving a much broader spectrum of bioregulatory purposes [35, 46, 
47]. 
In vivo studies allowed the assessment of the suggested distinct functions for IL-
2 and IL-15. The generation of knockout mice in which specific genes have been 
inactivated has helped to answer the central question of the redundancy IL-2/IL-15. 
Comparative studies of IL-2Rα – deficient and IL-2/15Rβ – deficient mice suggested 
that IL-15 might also be important for the differentiation of NK cells and certain subsets 
of intraepithelial lymphocytes (IEL) [48, 49]. Exogenous IL-15, but not IL-2, 
selectively induces the proliferation of memory phenotype CD8+ T-cells in normal mice 
[50]. Mice deficient in the IL-2 pathway (IL-2-/-, IL-2Rα-/- or IL-2Rβ-/-) have normal T-
cell development, however exhibit defects in peripheral lymphoid homeostasis and 
show evidence of incorrect T-cell activation, lymphoid infiltration and autoimmunity 
[45, 51-53]. The function specificity for IL-15 in vivo became clearer with the initial 
reports of IL-15 deficient (IL-15-/-) mice by Kennedy et al. [54], while IL-2-/- and IL-
2Rα-/- mice spontaneously activate T and B cells, dying from autoimmune disease, IL-
15-/- and IL-15Rα-/- mice are generally healthy, lymphopenic and lack NK cells, NKT 
cells, IEL subsets and activated CD8+ T-cells [46, 53, 54]. 
 
1.2.2. IL-15 expression and regulation of expression 
It is worth mentioning that the specificity of IL-15 arises from its pleiotropic 
characteristics, being expressed by a large variety of cells. While IL-2 is produced by 
activated T-cells, IL-15 is secreted by a wide variety of cells, including bone marrow 
stromal cells, gut and skin epithelia, macrophages and other cell types, but not by 
activated T-cells [35]. IL-15 mRNA is constitutively expressed by monocytes [55], 
macrophages [56], dendritic cells [57], keratinocytes [58], fibroblasts [59], kidney 
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epithelial cells [60], IEL [61], neural cells [62] and hepatocyte cells [63]. Additionally, 
IL-15 was also observed outside the lymphoid compartment, in particular brain [62], 
kidney [60], liver [64], and intestine [61]. 
Interestingly, despite this wide cellular distribution, it is extremely difficult to 
detect IL-15 in cell culture supernatants [32]. Indeed, most primary cells and cell lines 
which express IL-15 mRNA do not release detectable amounts of this cytokine into the 
culture medium [65-67]. This “striking” discrepancy between IL-15 mRNA and protein 
secretion is explained by the several lines of evidence indicating the existence of an 
intricated control of expression regulation at the levels of transcription, translation and 
intracellular trafficking and translocation [66-71]. 
 
1.2.3. IL-15 receptor complex 
As previously mentioned, the IL-15 cell-surface receptor is a complex 
constituted by a combination of three subunits – the IL-15Rγc, the IL-2/IL-15Rβ (both 
shared with IL-2) [72], and a private high-affinity subunit IL-15Rα. The ectodomain of 
IL-2Rβ and γc each consist of two fibronectin-type III domains, which participate in IL-
15 binding. Their cytoplasmic domains can sequester signaling molecules such as JAK1 
and JAK3 [73] hence being able to participate in both the ligand binding and signal 
transduction. 
As already mentioned, IL-2Rβ and γc are shared subunits of the IL-2 receptor, 
activating similar signaling pathways upon ligand binding, which may partially account 
for the overlapping functions of IL-15 and IL-2. A possible mechanism by which IL-15 
and IL-2 attain their distinct in vivo functions is through differences in the properties of 
their α-chain receptors. 
Recently, is has been demonstrated that IL-15Rα not only exists in a membrane-
bound form, but also in a soluble form (sIL-15Rα) [74, 75]. The presence of sIL-15Rα 
in circulation may negatively affect the availability of free IL-15, by the cytokine 
competition with the cognate membrane-bound receptors [74, 75], which may be the 
cause of the difficulty to detect free IL-15 [32]. 
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1.2.4. IL-15 and signaling 
Originally, IL-15Rα was thought to be a component of a heterotrimeric receptor 
complex containing IL-2/IL-15Rβ and γc chains that were required for signaling 
mediation [76]. Although IL-15Rα may, in some cases, act as a component of this 
receptor complex, more recent evidence indicates that IL-15Rα predominantly functions 
by presenting IL-15 to opposing cells expressing the IL-15Rβγ signaling components 
[76], and may expand IL-15 actions from autocrine or juxtacrine signaling to paracrine 
and endocrine communication mechanisms, including systemic cytokine effects [32, 
77]. 
The current theory of trans-presentation proposes the intracellular IL-15 binds to 
high affinity IL-15 binding protein (IL-15Rα), that is shuttled to the cell surface where it 
stimulates IL-15 signaling components on neighboring cells through cell-cell interaction 
[78]. In fact, supporting this theory there are accumulated evidence indicating that under 
physiological conditions, the biologically active form of IL-15 is actually surface-bound 
IL-15 [55, 59, 76, 79, 80]. 
Another important aspect of membrane-associated IL-15 is its ability to mediate 
reverse signaling events [32]. 
Each cytokine receptor seems to be coupled to a specific array of JAK and 
STAT, and given the similarities between IL-2 and IL-15 receptor, Johnston et al. found 
that IL-15 activates similar signaling pathways throughout JAK1 and JAK3, and then 
these rapidly induce the phosphorylation and activation of STAT3 and STAT5 [81]. 
The Janus-family tyrosine kinase-signal transducer and activator of transcription 
(JAK-STAT) signaling pathway is the major mechanism used by cytokines to 
transducer intracellular signals [82, 83]. Briefly, receptor-associated JAK, following 
ligand binding, become activated and catalyze phosphorylation of tyrosine residues in 
the receptor cytoplasmatic domains. These phosphorylated tyrosine residues, in turn, 
serve as “docking” sites for STAT proteins, which, at this point dissociate and are able 
to translocate to the nucleus where they act as transcription factors [82, 83]. 
In fact, it has been found that JAK-1 deficient mice exhibit defective 
lymphopoiesis, due to incorrect signaling by γc-dependent cytokines [84]. Additionally, 
mutation on the JAK3 gene was shown to result in abnormal NK-cell development, due 
to defective IL-15 signalling [85, 86]. Similarly, mice lacking STAT3 were found to 
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exhibit perinatal lethality [87] and STAT5a/b double-knockout mice show a severe 
defect in T-cell proliferation [88] and a total absence of NK-cell development [89]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. IL-15 receptor mediated intracellular signal transduction events in lymphocytes. IL-15 
activates JAK1/JAK3 and STAT3/STAT5. Additional pathways involve Syk kinase and PLCγ, Lck 
kinase, Shc, resulting in the activation of PI3K/Akt and Ras/Raf/MAPK cascades, that could lead to the 
subsequent expression of bcl-2, c-myc and c-fos/jun genes and NF-kB activation. Adapted from [32]. 
 
 
The specific signaling mediated by the IL-15 receptor takes place after receptor-
ligand interaction, when the associated JAK are brought into close apposition. In 
particular, the IL-2Rβ chain recruits JAK1, whereas IL-2Rγc activates JAK3, which in 
turn lead to the activation of STAT3 and STAT5, respectively. The cytoplasmatic 
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domain of the IL-2Rβ and γc subunits contains specific tyrosine residues that become 
activated upon ligand binding, serving as docking sites for STAT3 and STAT5 via the 
STAT Src homology 2 (SH2) domains. Subsequently, recruited STAT are 
phosphorylated by activated JAK. Hence, the phosphorylated STAT transcription 
factors form either homo-and/or heterodimers and translocate to the nucleus to bind to 
their target DNA regulatory elements and participate in the activation of gene 
expression [32] (Figure 1.2). 
Additionally, there have been described a number of other signaling pathways 
activated by IL-2 and IL-15R, namely, the phosphorylation of the Src tyrosine kinases 
family (Lck, Fyn and Lyn), Syk-kinases and Plc-γ and Shc, resulting in the activation of 
PI3K/Akt and Ras/Raf/MEK/MAPK cascades [32, 90, 91]. IL-15 has been shown to 
activate NF-kB and AP-1 transcription factors [32, 92] and to control c-myc [93]. 
Moreover, it can induce Bcl-2 or alternatively result in fos/jun activation [94] (Figure 
1.2). 
 
 
1.3. CD8
+
 NKT cells and NK receptors 
We have previously shown that IL-15 was able to induce antigen-independent 
expression of NKR in purified CD8+CD56- T cells, after a 12 day culture period [63], 
including Ig-like receptors (KIR2DL2/3, KIR2DL4 and KIR2DL2), lectin-like receptors 
(NKG2A), and de novo expression of CD56 and NKp46 [63]. To our knowledge, this 
was the first evidence of an antigen-independent NKR de novo expression by IL-15 in 
resting human peripheral blood CD8+CD56- T cells [63, 95]. Supporting our 
observations, Tang et al., have shown induction of natural cytotoxic receptors on 
umbilical cord blood T cells by IL-15, and that these cells were mainly on CD8+ and 
CD56+ T cells [96]. A different study reported that IL-15 could induce CD94/NKG2A 
expression, but not NKR belonging to the Ig-like family, in T cells activated by 
superantigens or allogenic cells [97]. 
In fact, in the last years it has been shown that NK receptors could be expressed, 
not only by NK cells, but also by T cells, however, in contrast to NK cells, for which 
stimulatory and inhibitory functions of NKR could be conveniently demonstrated, their 
function on CD8+ T cells is less clear. 
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Initial reports showed that minor subsets of T cells, mostly CD8+ T cells, from 
normal donors could express KIR [98, 99]. Mingari et al., have found that, along with 
KIR, CD94/NKG2A was also expressed in CD8+ T cells [97, 99]. In the last years, also 
activating receptors have been described to be expressed in T cells, namely, the NKG2D 
receptor has been found to be normally expressed in almost all CD8+ T cells, contrarily 
to the other NKR [100]. 
Curiously,  contraction of TCR repertoire in old age may be accompanied by 
induction of a diverse array of NKR [101], and it has been proposed that induction of 
NKR/KIR expression in aging T cells can be seen as a compensatory adaptation to 
maintain immune diversification [101, 102], representing the best example for a 
secondary level of diversification of the immune repertoire, most likely as an adaptation 
to the extension of lifespan [101, 103], 
Importantly, we have preliminary evidence indicating that some of the NKR 
expressed on IL-15-activated CD8+ T cells are functional and these cells display an in 
vitro cytotoxicity, show increased anti-apoptotic levels of bcl-2 and high granzyme 
B/perforin expression. Moreover, these cells secrete regulatory cytokines, such as IFN-
γ, TNF-α, IL-1β and IL-10, upon cross-linking of NK receptors [95]. These results 
suggest that IL-15 is capable of differentiating CD8+ T cells into NK-like T cells 
displaying a regulatory (effector/memory) phenotype. 
 
1.3.1. NK receptors: CD56, KIR and NKG 
The NK receptor CD56 is a membrane glycoprotein belonging to the Ig 
superfamily [104] and an immunophenotypic marker for several unique populations of 
PBL [105], being present on approximately 10% to 25% of peripheral blood 
lymphocytes, and on approximately 5% of CD3+ peripheral blood lymphocytes [106]. 
CD56 appears to be identical to the neural cell adhesion molecule (NCAM), a well-
characterized structure mediating homotypic and heterotypic cell-cell interactions [107-
110]. 
The core polypeptide of the CD56 adhesion molecule appears to be the 140 kDa 
isoform of NCAM, which contains six potential sites for N-linked glycosylation 
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extensively modified with polysialic acid [104, 110, 111]. The molecular weight of the 
CD56 heavily glycosylated protein (NKH-1 molecule) is 200 – 220 kDa [112, 113]. 
In humans, CD56 represents a prototypic marker of NK cells and is also found 
on a subset of CD4+ and CD8+ T cells [104]. On NK cells it defines two different 
subpopulations according to the cell-surface density of this marker, CD56dim and 
CD56bright NK cells, with differential phenotype and function [104, 114-116]. Regarding 
the CD3+CD56+ T lymphocytes it comprises a unique subset of cytotoxic T 
lymphocytes that mediates non–major histocompatibility complex (MHC)-restricted 
cytotoxicity [117]. 
In contrast to NK cells, CD56 expression on T cells is not constitutive. It has 
been observed that CD56+ T cells are almost absent at birth and in adults are found as 
oligoclonal expansions [104]. CD8+CD56+ T cells generally contain high amounts of 
intracellular perforin and granzyme B, and CD56 expression on CD8+ T cells correlates 
with cytolytic activity [95, 104]. The finding that CD8+CD28- T cells have low 
telomerase activity and frequently express CD56, further supports the idea that CD56+ T 
cells have an effector/memory phenotype [118]. CD56+ T lymphocytes are believed to 
be major players in immune-surveillance and anti-tumor responses. Thus, the 
mechanisms by which these cells home into tumors and areas of inflammation are of 
great relevance to human health and disease [105].  
In addition to CD56, human NK cell responses result from the integration of 
signals from both cytokine receptors and germline-encoded NK cell inhibitory and 
activation receptors [119]. Major families of these cell surface receptors that inhibit and 
activate NK cells to lyse target cells have been characterized, including killer cell 
immunoglobulin-like receptors (KIRs), C-type lectins, and natural cytotoxicity 
receptors (NCR) [119, 120]. It is now clear that NK cell function is strictly regulated by 
the balanced triggering between positive and negative signals provided by their 
activating or inhibitory NKR [121, 122]. Activating receptors (activating KIR, 
CD94/NKG2C, NKG2D) are characterized by short cytoplasmic domains lacking signal 
transduction elements, and they associate with common transmembrane adaptor 
proteins such as CD3ζ, FcεRγ and DAP12, containing cytoplasmic tails with 
immunoreceptor tyrosine-based activation motifs (ITAM) [120, 121, 123]. Ligation of 
NK-activating receptors with membrane-bound molecules of target cells results in NK 
cell blastogenesis, cytokine production, cytotoxicity, and migration [120]. On the other 
Introduction 
 
13 
 
hand, inhibitory receptors (inhibitory KIR, CD94/NKG2A) recognize and engage their 
ligands, MHC class I molecules (HLA), on the surface of the target cell, thereby 
initiating an inhibitory signal [120, 121, 123]. Although the extracellular domains of 
NK cell inhibitory receptors are diverse, the intracytoplasmic signaling motifs of these 
transmembrane receptors are remarkably similar, known as immunoreceptor tyrosine-
based inhibitory motifs (ITIM) [121, 124]. 
Even though NK cells are prepared to rapidly kill abnormal cells, it is important 
to mention that they are normally restrained by these inhibitory receptors, and it has 
been proposed that NK cells all express at least one inhibitory receptor to provide NK 
cell tolerance and to prevent inappropriate NK cell responses directed at self [119, 124].  
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II. Aims of the thesis 
The main objective of this thesis was to ascertain the optimal culture conditions 
for the long-term culture of ex vivo CD8+ T cells in order to study their phenotypic 
features. 
The specific aims were: 
 
1. To compare the effect of chronic stimulation with IL-15 alone or in combination 
with PHA on the growth and survival of ex vivo CD8+ T cells.  
 
2. To monitor cellular parameters of long-term cultured CD8+ T cells, namely size 
and complexity.  
 
3. To correlate growth and survival with expression of CD56. 
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III. Material and Methods 
3.1. Isolation of peripheral blood lymphocytes 
In this study we have used Buffy Coats of healthy blood donors from Instituto 
Português do Sangue and Hospital de São João, Porto. 
Peripheral mononuclear cells (PBMC) were obtained from these buffy coats after 
gradient density centrifugation over Lymphoprep (Nycomed, Norway). First, buffy 
coats were diluted on PBS 1x (13 mM Na2HPO4, 7mM NaHPO4, 100 mM NaCl, pH 
7.0) 1:1, put over Lymphoprep (2:1) and centrifuged at 2200 rpm for 20 minutes 
without brake. The PBMC were collected from the ring at the interface between 
Lymphoprep and plasma, and washed with PBS 1x solution followed by centrifugation 
at 1500 rpm, 10 minutes to remove traces of Lymphoprep.  
Contaminating red blood cells were lysed in pre-heated lysis solution (10 mM 
Tris, 150 mM NH4Cl, pH 7.4), for 10 minutes at 37 ºC. Subsequently, PBMC were 
plated in non-adherent surface Petri dishes in 10 mL RPMI (5% FBSi, 1% 
Penicilin/Streptomycin/Amphotericin B (PSA)), at a density of 5x106 PBMC/mL. 
Following overnight culture peripheral blood lymphocytes (PBL) were obtained, and 
counted. Two brands of RPMI were used (Gibco, Invitrogen, UK; and Lonza, 
BioWhittaker, Belgium). Fetal bovine serum was from PAA, Germany and PSA was 
purchased from Gibco, Invitrogen, UK. 
 
3.2. Magnetic T CD8
+
 cell purification 
Starting from the previously isolated PBL, purified CD8+CD56- were obtained by 
magnetic isolation, using one of the following approaches.  
 
3.2.1. Isolation of untouched human CD8
+
 T cells  
 
Magnetic labelling 
Isolation of untouched CD8+ T cells was done using a CD8+ T cell isolation kit 
(see below) (Miltenyi Biotec, Germany). PBL were centrifuged at 1500 rpm, 10 
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minutes, and the pellet was ressuspended in 400 µL of wash buffer (PBS 1x, 2mM 
EDTA, 10% BSA) per 100x106 total cells. Afterwards, the CD8+ T cell Biotin-antibody 
Cocktail (Cat #130-096-495 or #130-094-156) was added, 50 µL per 100x106 total cells, 
and cells were incubated for 10 minutes at 4 ºC. Next, 300 µL of wash buffer per 
100x106 cells were added, followed by 100 µL of CD8+ Cell Microbead Cocktail (Cat 
#130-096-495 or #130-094-156) per 100x106 total cells. Then, cells were incubated, for 
the second time, for 15 minutes at 4 ºC. Finally, cells were washed with 1-2 mL of wash 
buffer by centrifuging at 1500 rpm, 10 minutes, and ressuspended in 500 µL of wash 
buffer per 100x106 of total cells. 
 
Magnetic separation using LS columns 
A LS column (Cat #130-042-401, Miltenyi Biotec, Germany) was placed in the 
magnetic field of a suitable magnetic-activated cell sorter (MACS) separator 
(MidiMACS separator, Miltenyi Biotec, Germany) and prepared by rinsing with 3 mL 
of wash buffer. The cell suspension previously magnetically labeled was applied onto 
the column (maximum number of labeled cells/column - 108), and the total effluent, 
representing the enriched CD8+ T cells was collected. Further column washing steps 
(3x1 mL) were performed with wash buffer to increase CD8+ T cell recovery. 
 
3.2.2. Positive selection of human CD8
+
 T cells after CD56 depletion 
 
Magnetic labelling – CD56 depletion 
PBL were centrifuged at 1500 rpm, 10 minutes, and the pellet was ressuspended in 
800 µL of wash buffer per 100x106 total cells. The CD56 Microbeads (Cat #130-050-
401, Miltenyi Biotec, Germany) were added, 200 µL per 100x106 total cells, and cells 
were incubated for 15 minutes at 4 ºC. Next, cells were washed with 1-2 mL of wash 
buffer and centrifuged at 1500 rpm, 10 minutes, to remove non-binded beads, and 
ressuspended in 500 µL of wash buffer per 100x106 of total cells. 
 
 
Material and Methods 
 
17 
 
Magnetic separation using LD columns 
The LD column (Cat #130-042-901, Miltenyi Biotec, Germany) was placed in 
the magnetic field of a suitable MACS separator (MidiMACS separator) and prepared 
by rinsing with 2 mL of wash buffer. The cell suspension previously magnetically 
labeled was applied onto the column (maximum number of labeled cells/column - 108), 
and the total effluent, representing the CD56 depleted cells was collected. Further 
column washing steps (2x1 mL) were performed with wash buffer to increase cell 
recovery. 
 
Magnetic labelling – CD8 positive selection 
CD56 depleted cells were centrifuged at 1500 rpm, 10 minutes, and the pellet was 
ressuspended in 800 µL of wash buffer per 100x106 total cells. The CD8 microbeads 
(Cat #130-045-201, Miltenyi Biotec, Germany) were added, 60 µL per 100x106 total 
cells, and cells were incubated for 15 minutes at 4 ºC. Next, cells were washed with 1-2 
mL of wash buffer by centrifuging at 1500 rpm, 10 minutes, to remove un-binded 
beads, and ressuspended in 500 µL of wash buffer per 100x106 of total cells. 
 
Magnetic separation using LS columns 
The LS column was placed in the magnetic field of a suitable MACS separator 
(MidiMACS separator) and prepared by rinsing with 3 mL of wash buffer. The cell 
suspension previously magnetically labeled was applied onto the column (maximum 
number of total cells/column - 108), and the total effluent, representing the unlabelled 
cell fraction was collected. Further column washing steps (3x1 mL) were performed 
with wash buffer to optimize separation. Subsequently, the column was removed from 
the separator and placed in a suitable collection tube, and 5 mL of wash buffer were 
pipetted onto the column. Using the plunger supplied with the column, the enriched 
CD8+ T cells were flushed out.  
 
After collection of CD8+ T lymphocytes, cells they were centrifuged at 1500 
rpm for 5 minutes and counted using trypan blue exclusion test. 
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3.3. Cell culture conditions 
After purification, CD8+CD56- T cells were cultured in RPMI (10% HSi, 1% 
PSA), at 37 ºC, 5% CO2, 95% humidity. Inactivated human serum was from PAA, 
Germany. Cultures were set-up at 1.0x106 cells/mL on 24-well plates, and IL-15 (R&D 
Systems, USA) was added to a final concentration of 10 ng/mL. Cells were monitored 
daily through visual and microscopic observation to ensure optimal cell growth and 
contamination control and prevention.  
Every 7 days cells were washed (1500 rpm, 5 minutes), counted and 
ressuspended on fresh RPMI (10% HSi, 1% PSA) to a final concentration of 1.0x106 
cells/mL. Fresh IL-15 was added to a final concentration of 10 ng/mL. Every 14 days 
besides renewal of IL-15, cyclic cell restimulation was done by TCR-dependent stimuli 
using PHA (Sigma Aldrich, USA) at a final concentration of 1 µg/mL. 
Besides this cell culture condition, the human enriched CD8+ T-cells isolated 
from PBMC were cultured in vitro under two other different culture conditions: on day 
7, some cultures were splitted in two conditions: those stimulated with IL-15 and those 
washed and replated without IL-15, hence with medium alone (Figure 4.1). The cell 
cultures that were restimulated on day 7 with IL-15, when reached 14 days of culture 
were splitted again and some were cultured with only IL-15. These will be the cultures 
further designated and treated as controls. The remaining cultures were restimulated 
with PHA, alongside with IL-15, as described above. Those cultures where early IL-15 
withdrawn was performed, from day 14 cell cultures were restimulated on a TCR-
dependent manner with PHA and IL-15. 
In some experiments, 100 U/mL of IL-2 (Tecin, USA) was added on day 14 
instead of PHA (Figure 4.4) 
 
3.4. Flow cytometry analysis 
Cells were harvested, counted and between 0.25x106 to 1x106 cells were used for 
extracellular FACS staining. Then, cells were centrifuged at 1200 rpm, 2 minutes in 96 
well round-bottom plates, and incubated with 50 µL of diluted appropriate antibody 
(ies) (Table 3.1) on staining buffer (PBS 1x, 0.2% BSA, 0.1% NaN3) at 4 ºC for 30 
minutes, in the dark and on ice. Negative controls (without anti-CD56 antibodies) were 
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also performed in each staining. Afterwards, cells were then washed again with staining 
buffer at 1200 rpm, 2 minutes. Cells were ressuspended in 200 µL of PBS 1x, and 
transferred to a FACS tube in a final volume of 300 µL. 
 
Table 3.1. List of antibodies used on FACS extracellular staining. 
Antibody Clone Isotype Conjugate Company Dilution 
CD8 MEM-31 IgG2a PE Immunotools 1:10 
CD8 DK25 IgG1 FITC Dako 1:10 
CD56 B159 IgG1 k Alexa 488 BD Biosciences 1:20 
CD56 B159 IgG1 PE Immunotools 1:10 
 
 
Extracellular stained samples were acquired in a Coulter Epics XL (Beckman-Coulter) 
flow cytometer. For each sample 10.000 events were normally acquired in the 
lymphocyte gate defined using FS/SS parameters. Data were subsequently analyzed 
using the System II Coulter Epics XL software. 
The individual analysis was done using the following approaches: 1) Setting of 
gates to delimit four different regions (A - resting lymphocytes, B - blast cells, C -dead 
cells (as determined by propidium iodide positivity), D – Live cells), 2) Determination 
of cell size and complexity according to FS/SS parameters and 3) CD56 expression – 
the relative percentage of CD56+ T cells from total CD8+ T cells was calculated. 
 
3.5. Statistical Analysis  
Statistical analysis was performed using Excel 2007 and IBM SPSS Statistics 2.0 
(SPSS Inc. USA) softwares. Student T-test (for paired and independent samples) was 
used to determine the significance of the differences between group means. Pearson’s 
correlation was used to assess the correlation between continuous variables (FS/SS and 
weeks in culture). Statistical significance was defined as p<0.05.  
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IV. Results 
4.1. IL-15 and PHA are necessary to keep CD8
+
 T cells growing 
In order to establish the best approach to perform long-term cultures of isolated CD8+ 
T lymphocytes, the number of live cells at the end of each 7 day period was registered, 
as described in material and methods. The concentration of cells in all cultures from 
days 0 to 21 was calculated, and the results obtained are depicted on Figure 4.1 
(mean±SEM). 
Since the initial lymphocyte concentration each week was 1x106 cells per mL, 
this was the reference value, and the cultures quality was examined verifying 
fluctuations above or below this cut-off. 
Thus, starting from an average of 1x106 cells per mL (number of experiments, 
n=10), it was observed a slight but significant decrease (p=0.002) on cell number after 
the first week to 0.72x106±0.02x106 cells per well (mean±SEM). On day 14, the 
splitted cultures refreshed with IL-15 on day 7 showed a statistically significant 
(p=0.010) doubling on lymphocyte numbers to 1.43x106±0.07x106 cells per well 
(n=10). In contrast, the same cultures subjected to IL-15 removal, drastically decreased 
(p<0.001) their average cell concentration, by more than 50% (0.33x106±0.01x106 cells 
per well, n=3). These cells, were not able to recover optimal cell growth by day 21 
(0.40x106±0.14x106 cells per well; p=0.786, n=2), even after IL-15 and PHA addition 
on day 14, eventually disappearing thereafter. The effect of restimulation with PHA on 
day 14 was quite striking. Indeed, while where PHA was omitted, the cell recovery 
decreased from 1.43x106±0.07x106 cells per well to 0.30x106±0.02x106 cells per well 
(n=2, p=0.001), and these lymphocytes eventually disappeared, thereafter cell cultures 
restimulated via TCR with PHA maintained on day 21 a cellular concentration well 
above the one million cut-off (1.67x106±0.08x106 cells per well, n=9), revealing a 
slight increase when compared to day 14, although not statistically significant 
(p=0.449). 
Based on these results, subsequent cultures were carried out with the continuous 
presence of IL-15 (added in fresh medium every 7 days) and addition of PHA every 14 
days.  
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Figure 4.1. Study of different culture conditions. (A) Representative scheme of the different culture 
conditions performed. (B) Plot showing the cell concentration (mean±SEM) over time of culture. Green 
dash dot lines represent cell cultures subjected to IL-15 withdrawal on day 7; blue dash lines correspond 
to cell cultures restimulated on day 14 only with IL-15; red solid line stands for cell cultures restimulated 
with PHA, every 14 days.  
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4.2. IL-15 is necessary to maintain CD8
+
 T cell viability and cell 
growth  
In order to further analyze the effect of IL-15 withdrawal from cell cultures on 
day 7, we analysed cell viability and cell growth. While the percentage of surviving 
cells was calculated after subtraction of dead cells (as determined by a decrease in FS), 
the percentage of cells that increased their size was calculated by gating on cells with an 
overall increase in FS and SS. We have previously shown that dead cells have a reduced 
FS and are positive for propidium iodide, a marker of non-viable cells [125] positivity 
(see also Fig. 4.6A). 
As can be seen in Figure 4.2, IL-15 withdrawal affected negatively cell viability 
and the percentage of blast cells. Hence, from a cell viability of 75.3±3.9 % on day 7 
(n=5), cultures subjected to IL-15 removal decreased to 32.3±12.0 % on day 14 
(p=0.008). This was in marked contrast to cultures in the presence of IL-15, where the 
number of live cells was about 63.2±6.9 %. The difference observed on day 14 between 
these two culture conditions was statistically significant, p=0.007. 
Regarding the percentage of blast cells (Figure 4.2B), cultures subjected to IL-15 
withdrawal showed a marked decrease from 20.1±6.7 % on day 7 (p=0.050) to 1.9±0.9 
% (n=5) on day 14. In marked contrast, cultures with IL-15 showed a 21.7±3.9 % of 
blasts on day 14 (n=5). The difference on the percentage of blast cells between these 
two culture conditions on day 14 was statistically significant (p=0.004).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Early IL-15 withdrawal markedly affects cell viability and blast cells count. (A) 
Percentage of live cells over time of culture. (B) Percentage of blast cells over time of culture. (A) and 
(B) represent mean±SEM values from five experiments. Paired student T-test. The level of significance 
was set at p<0.05. 
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4.3. PHA signals downregulate CD56 expression levels in IL-15 
differentiated CD8
+
 T cells 
A detailed study regarding the percentage of CD8+ CD56+ cells was done along 
a 28 days culture period. Cell cultures where PHA was absent on day 14 were used as 
controls (Figures 4.3 and 4.4). 
The results suggest a progressive increase on the percentage of CD56+ cells until 
day 14. Accordingly, in the cell cultures (condition D14 + PHA), after one week it was 
observed a statistically significant increase (p=0.001) on the relative percentage of 
CD56+ cells from 4.6±1.8 to 14.5±3.7 (mean±SEM, n=11). The same behavior was 
verified on day 14, when the percentage of CD56+ cells accounted for 25.4±4.6 of total 
CD8+ cells (n=11, p<0.001) (Figure 4.4). 
Interestingly, IL-15 withdrawal on day 7 affected negatively the percentage of 
CD56+ cells (Figure 4.3). Thus, while cells grown in the presence of IL-15 for 14 days 
showed a percentage of CD56+ cells of 14.3±2.8%, cell cultures where IL-15 was 
removed showed only 3.8±1.3% of CD56+ cells (n=5). Again, the difference between 
these two conditions was statistically significant (p=0.004). 
A striking pattern modification took place on day 21 in cultures where PHA was 
added on day 14, where a clear decrease on the percentage of CD56+ cells was observed 
(25.4±4.6 versus 7.0±1.0 %, n=8, p=0.004). Contrarily, in control cultures without 
PHA, such decrease was not verified (25.4±4.6 versus 20.2±8.3; n=3; p=0.132). 
This pattern was not seen when IL-2 was added on day 14 instead of PHA 
(Figure 4.5).  
Even though the addition of PHA affected the percentage of CD56+ cells, it was 
a temporary and reversible effect. In fact, from day 21 to day 28 it was found that cell 
cultures recovered to a percentage of CD56+ cells of 15.1±3.4 % (n=4, p=0.047, Figure 
4.3A). 
No addition of PHA on day 14 led to a decrease of CD56+ cells on day 28. 
However, this refers to the only one experiment that achieved this day in this culture 
condition. 
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Figure 4.3. Early IL-15 withdrawal markedly affects CD56
+
 cells. (A) Percentage of live cells over 
time of culture. (A) Represents mean±SEM values from five experiments. Paired student’s t-test. The 
level of significance was set at p<0.05. (B) Representative flow cytometry data showing the differences 
on the percentage of CD8+CD56+ T cells after cytokine removal at day 14. Histograms show CD56 
expression on live CD8+ T cells (region D on dot-plots). 
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Figure 4.4 PHA addition on day 14 negatively affected the percentage of CD56
percentage of CD56+ cells over days in culture. Data depicted are the mean
of CD56+ cells, gated on live CD8
student T-test.. (B) Representative histograms, gated on live CD8
experiments where PHA was added (upper graphs) or omitted (lower graphs) on day 14.
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Figure 4.5. PHA, but not IL-2, adding negatively affects the relative percentage of CD56
from two different experiments. 
 
4.4. CD56 expression takes place preferentially on blast 
Next, we wanted to ascertain whether cellular transformation influenced the 
expression of CD56. It was found that 
at any point (p<0.05, Figure 
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Figure 4.6. CD56 is preferentially expressed on blast cells.
aforementioned analysis gates (A stands for non
cells). (B) Representative dot-plots for two experiments
CD56+ cells over days in culture. Data depicted are the mean
cells, gated in blast and non-blast cell region. P
p<0.05. 
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4.5. CD56
 
expression in long-term cultures of CD8
+
 T cells 
To ascertain whether the up and down CD56 modulation seen when PHA was 
added on day 14 could be observed in long-term cultures, three CD8+ T cells samples 
were cultured up to nine weeks in the continuous presence of IL-15 and the addition of 
PHA at weeks 2, 4, 6 and 8. As illustrated in Figure 4.7, all three cultures behaved 
similarly during the first 4 weeks, with CD56+ cells decreasing one week after addition 
of PHA and increasing two weeks later. This spiky pattern (up and down) was 
maintained in sample 1 until the end of the culture, while in sample 2 only lasted until 
week six, at which time a steady increase in the percentage of CD8+CD56+ T cells was 
observed until week nine. This increase was most striking in sample number 3, where 
the percentage of CD8+CD56+ T cells increased by more than two fold between week 
four and nine. 
 
 
Figure 4.7. Percentage of CD56
+
 cells in long-term cultures. Data of three different experiments. The 
percentage of CD56 was calculated on gate of alive cells and CD8+ T cells. 
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4.6. Long-term cultures of CD8
+
 T cells with IL-15 and PHA increases 
the overall size and complexity of the cells 
In general, the percentage of alive cells exceeded the percentage of dead cells, 
throughout the culture period (Figure 4.8). However, after eight weeks, most cultures 
showed a decline in the percentage of live cells.  
 
 
 
The following phenotypic features studied were the forward scatter (FS) and side 
scatter (SS) parameters, in order to analyze CD8+ T cell size and cellular complexity 
throughout time (n=11). Figure 4.8 plots the dispersion of mean fluorescence intensity 
(MFI) values of FS/SS over the days in culture. 
Figure 4.8. Percentage of live cells in long-term cultures. Scatter plot showing the percentage of live cells along the 
culture period.  Each circle represents a different experiment (n=11). Only 50% of the cultures survived until week 10. 
This number was reduced to two by week 12.  
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There was a positive and statistically significant (p<0.001) correlation between 
both FS (r=0.494) and SS (r=0.584) parameters and time of cell culture period.  
Interestingly, once cells become larger and more complex they did not return to 
their initial status exhibited on day 0.  
In spite of this global increase of FS/SS parameters, the day-specific analysis 
provides additional data. Thus, one week after adding PHA (week 3, 5, 7…), a 
notorious enhancement on cell size and on lymphocyte complexity and granularity 
(although less perceptible) was observed.  
 
 
  
Figure 4.9. Cellular parameter (FS/SS) of cells over time. Data from 11 experiments. Pearson coefficient 
correlations and p values are depicted. The level of significance was set at p<0.05. Squares and straight line denote 
FS and circles and dotted line denote SS. Each square/circle represents the live cell gate MFI of an experiment on 
each week (n=109). 
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V. Discussion 
5.1. IL-15 and PHA: a good combination to keep CD8
+
 T cells alive 
and growing 
The main objective of this work was to establish a good and reliable cell culture 
method to keep in culture ex vivo CD8+ T lymphocytes for long periods of time using 
IL-15 as the main stimulus. By combining IL-15 with addition of PHA every two weeks 
we have been capable to maintain ex vivo human CD8+ T cells in culture for more than 
90 days.  
It is well known that IL-15 is a T cell growth factor which main biological 
functions are the inhibition of apoptosis and the stimulation of cell proliferation. In vivo 
studies have demonstrated that IL-15 functions during all four phases of the T-cell 
immune response: initiation, expansion, clonal deletion and memory generation [126], 
and specifically regulates the survival and proliferation of memory CD8+ T cells under 
normal physiological conditions [127]. Indeed, long-term survival of CD8+ memory T 
cells is critically dependent on this cytokine [46, 128, 129]. The key role played by IL-
15 in vivo became clear with the initial reports showing that IL-15-/- and IL-15Rα-/- mice 
are lymphopenic and lack NK cells, NKT cells, IEL subsets and activated CD8+ T cells 
[46, 53, 54]. Interestingly, administration of recombinant IL-15 has been shown to 
selectively stimulate the proliferation of memory phenotype CD8+ T cells both in vivo 
and in vitro [50].  
Previous in vitro studies have focused on IL-15 effects on short-term T cell 
cultures [12, 25, 130]. Thus, we have previously shown that IL-15 is capable to activate 
and drive into proliferation human CD8+ T cells in an antigen-independent, that is 
without TCR stimulation, during a 7-day culture period, suggesting a generic influence 
of this cytokine on CD8+ T cell proliferation and survival [12]. In another study, the 
effect of exogenous IL-15 on the in vitro expansion of CD3+CD56+ NKT-like cells 
present in cord blood mononuclear cells samples was explored in 14-day cultures [27]. 
Despite these remarkable effects CD8+ T cell homeostasis, IL-15 biological activities in 
vitro are not long lasting and to our knowledge, there are no reports of long-term 
cultures of CD8+ T cells with only IL-15. 
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In the present study, we were able to keep optimal numbers of live CD8+ T cells 
in culture with IL-15 for up to 21 days, but not beyond. Importantly, IL-15 had to be 
freshly added each week to the cultures in order to keep CD8+ T cell alive, indicating 
that its continuous presence is necessary to avoid CD8+ T cells apoptosis. In this regard, 
it is important to refer that one of the main biological properties of IL-15 is related with 
its capacity to inhibit apoptosis in multiple systems [131-133], including prevention of 
IL-2 dependent activation induced cell death (AICD) [134], presumably by upregulating 
anti-apoptotic proteins such as Bcl-2 and Mcl-1 [135-140]. Most likely, the continuous 
presence of IL-15 in the cultures is improving the survival of our in vitro cultured CD8+ 
T cells by upregulating pro-survival factors. Our recent work showing that CD8+CD56+ 
T cells cultured for 12 days with IL-15 express high levels of the anti-apoptotic protein 
Bcl-2 [95], supports this assumption. The results of this study are also in agreement 
with the fact that in the absence of proliferative IL-15 signals, memory CD8+ T cells 
undergo a slow atrophy in number, until they become essentially undetectable [127, 
128, 141], which is in line with our observation that IL-15 withdrawal at day 7 
drastically decreased CD8+ T cell viability and numbers on day 14. 
It is well known that human CD8+ CTL are difficult to maintain in culture for 
long periods of time (>3 weeks) without the eventual loss of viability, requiring periodic 
stimulation with either antigen, anti-TCR antibodies or mitogenic agents such as PHA, 
which ideally should be provided in combination with feeder cells that function as 
antigen presenting cells (APC) and the appropriate cytokines to proliferate [28]. Having 
this in mind, and in order to overcome the temporal limitations of the cell growth and 
survival bioactivities of IL-15, we decided to combine IL-15 with a TCR-mediated 
stimulus. PHA was the choice because it binds to the TCR/CD3 complex, mimicking all 
the intracellular activation events triggered by anti-CD3 antibodies [142-144], and does 
not interfere with functional and phenotypic characteristics of the activated T cells. 
Previous studies have already shown that it is possible to carry out long-term cultures 
human CD8+ T cells. Lu et al, by using IL-15 added every 2/3 days in combination with 
anti-CD3 antibodies and the presence of irradiated feeder cells were able to grow CD8+ 
T cell for up to 80 days [28]. Also, Li et al. used IL-15 stimulation every 10 days, with 
anti-CD3/CD28 stimulation at seeding, providing the crucial TCR signal, and were able 
to grow human T CD8+ cells for 45 to 80 days in culture [29]. 
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Noteworthy, when PHA was included in the stimulus protocol, we found that it 
helped to keep IL-15-stimulated CD8+ T cell cultures for much longer periods of time 
when added every two weeks. Under these conditions, some cultures of CD8+ T cells 
lasted up to 90 days. The molecular basis for this successful combination is presently 
not known, but could be related with the establishment of a correct balance between 
proliferative signals (PHA) and pro-survival signals (IL-15). Thus, PHA is a potent T 
cell mitogen that induces T cell blastogenesis and proliferation when accessory signals 
are present  [145].  Yet, proliferating T cells, especially at S phase of the cell cycle, are 
susceptible to apoptosis [146]. Thus, in spite of inducing cell proliferation, PHA also 
promotes cell apoptosis due to Fas-FasL interactions [147], which can be inhibited by 
IL-15  [131]. Thus, the combination of PHA and IL-15 signals apparently creates a 
favorable environment for CD8+ T cells to grow and expand. While PHA mainly 
promotes the entrance into the cell cycle, IL-15 contributes to basal levels of 
proliferation and protection from apoptosis. In this context, it has been proposed that IL-
15 acts as a survival factor that induces a quiescent state in T cells that helps them to 
survive in the absence of TCR engagement [148]. 
In support of this assertion are studies showing that IL-15 can augment the anti-
CD3 and PHA proliferation and cytokine production of both mouse and human CD8+ T 
cells induced by anti-CD3 antibodies and PHA [37, 130, 149-151]. Moreover, a recent 
study comparing the differential effect of IL-15 and IL-2 on survival of PHA-activated 
cord blood and adult peripheral blood T lymphocytes showed that IL-15 enhanced the 
survival of cord blood PHA-activated T cells by decreasing the caspase-3+ population 
and by increasing the Bcl-2+ population [152]. Finally, Seder et al. demonstrated that 
IL-15 enhanced proliferative responses by PBMC obtained from HIV-1– infected 
individuals in response to antigens or mitogen [153].  
Overall, our results suggest that the combination of TCR-independent (IL-15) 
and TCR-dependent (PHA) signals keeps CD8+ T cells into a continuous proliferation 
and survival process. Yet, even though our IL-15/PHA cell cultures were viable during 
most of their life span, viability started to decline after two/three months, indicating that 
that IL-15 signaling combined with alternated PHA stimulation is not enough for 
maintaining long-term CD8+ T cell growth. Most likely, and in resemblance with 
senescence models or natural ageing, this suggests that proliferation/survival signals 
other than those provided by IL-15 and PHA are lacking in our in vitro system. 
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5.2. IL-15/PHA stimulated CD8
+
 T cells: a good model to study 
differentiation 
Taking advantage of the positive effect of the combination of IL-15 and PHA on 
CD8+ T cell growth and survival, we decided to examine the differentiation status of the 
cultured CD8+ T cells by analyzing cell size and complexity akin to CD56 expression. 
The results of this analysis showed that IL-15/PHA stimulated CD8+ T cells acquired a 
large granular morphology and a fraction of these cells, mostly blast cells, expressed 
CD56, the prototypic marker of NKT cells.   
We have recently shown that IL-15 per se is capable of driving purified 
CD8+CD56- T cells into a TCR-independent program of differentiation that is 
associated with the acquisition and upregulation of typical NK receptors, resulting in the 
generation of CD8+CD56+ T cells co-expressing other NK receptors, such as several 
KIR and NKp46 [95]. Although these studies were performed during a short window of 
time (7-12 days), they laid the grounds to explore further the biological activities of IL-
15 on CD8+ T cells during longer period of times. 
Taking into account that CD56 is a good marker of de novo NKR expression by 
IL-15-differentiated CD8+ T cells, we assessed the expression profile of this typical NK 
receptor on ex vivo CD8+CD56- T cells cultured for periods longer than 12 days with the 
IL-15/PHA combination. 
In view of the influence of IL-15 on CD56 upregulation by CD8+ T cells, the 
cytokine early withdrawal from cell cultures resulted in a decrease the percentage of 
CD8+CD56+ T lymphocytes. Since IL-15 per se is capable of inducing de novo 
expression of some typical NK receptors, such as NKp46, it is tempting to speculate 
that IL-15 withdrawal would likely affect also their expression. 
A detailed study of the percentage of CD8+CD56+ cells along the whole culture 
period revealed the negative impact that PHA stimulation had on CD56 expression, with 
a consistent decrease following PHA addition during the first 4-6 weeks of culture. 
These data suggest the existence of a close relationship between PHA stimulation of 
chronically activated CD8+ T cells and CD56 expression.  
One could hypothesize that, perhaps, PHA was “masking” some CD56 epitopes. 
This comes from the fact that PHA binds to glycosylated residues on the TCR/CD3 
complex [10, 11, 143, 144]. Being CD56 a heavily glycosylated molecule [112, 113] 
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there is the possibility that PHA was blocking some anti-CD56 antibody binding sites. 
However, since the binding of PHA to the TCR/CD3 complex is temporary, the same 
may be argued for its putative binding to CD56, ruling out a possible “masking” effect. 
Therefore, the PHA-induced CD56 decrease must be due to other mechanisms, for 
instance, the hypothetic activation of common signaling pathways between TCR and 
IL-15.  
Interestingly, both IL-15 and TCR-engagement (through CD3 stimulation) are 
capable of inducing CD8+ memory T-cells proliferation, suggesting that these two 
pathways share some common downstream events, despite apparent differences in the 
initial ligand-receptor interaction [154]. Moreover, it was found that these two stimuli 
induce highly similar responses, showing that many of the genes involved in signal 
transduction, transcription regulation, T cell activation, cell cycle, apoptosis, and 
effector functions, which are characteristic changes of TCR-mediated activation, are 
expressed upon IL-15 activation, suggesting that both stimuli effectively turn on the cell 
cycle machinery in memory phenotype CD8+ T cells [154]. Therefore, we suggest that 
TCR activation following PHA stimuli could interfere with IL-15 intracellular 
signaling, affecting the CD56 expression induction by IL-15 (Figure 1.2).  
Due to this seemingly overlapping downstream events and induction of similar 
gene expression and effector function, we hypothesize that PHA may be competing with 
IL-15 for intracellular cascade ligands, decreasing the available molecules that mediate 
the  IL-15-induced CD56 upregulation (Figure 5.1). Indeed, the addition of IL-2 on day 
14, instead of PHA, did not result on a decrease in CD56 expression. Only when 
restimulation was done with PHA CD8+ T cells downregulated CD56 expression, 
suggesting that TCR-mediated activation works as a negative feedback for CD56 
expression. Moreover, the negative effect of PHA on the percentage of CD8+CD56+ T 
cells from day 21 to day 28 was reversed by replacing PHA by fresh IL-15, suggesting a 
temporary and reversible effect. Alternatively, the decrease on CD56 expression could 
be the result of an enhanced apoptosis after PHA addition, suggesting that CD56 down-
modulation is a consequence of PHA-stimulation. 
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Figure 5.1. Signalling pathways of IL-15, IL-2 and PHA-TCR. (A) IL-15 and IL-2 activate similar 
signaling pathways throughout activation of JAK/STAT, meaning they should dictate a common biologic 
outcome. However, the fact they do not means there are differences in the signaling pathways triggered 
by each cytokine, explaining their unique functions [26, 35, 46, 47] (B) The different initial signaling 
events of both IL-15 receptor and TCR complex deliver significantly overlapping downstream signals 
[154] in memory phenotype CD8+ T cells in vitro, leading to similar gene expression. PHA may be 
competing with IL-15 for intracellular cascade ligands, affecting negatively the expression of CD56 
(dotted line). 
 
 
It appears that the signaling pathways through IL-15 receptor and the TCR 
complex deliver significantly overlapping downstream signals in CD8+ T cells in vitro. 
These preliminary results need to be corroborated and extended in order to unravel the 
molecular mechanism behind the PHA interference on CD56 expression 
 In this study, we have also shown that CD56 is preferentially expressed by blast-
like CD8+ T cells. Although the reason for this finding is presently unknown, a possible 
explanation might take into account an epigenetic mechanism, such as modulation of 
the methylation status of the transcriptional active region, taking place during active cell 
proliferation [155]. Accordingly, it was found that the promoting region of CD56 gene 
is located on a GC rich domain, containing high number of CpG dinucleotides, which 
renders this promoter an excellent candidate to methylation [156]. Hence, while 
increased methylation in the promoter region of a gene leads to reduced expression, 
demethylation could render the gene constitutively expressed [155]. In fact, in contrast 
to NK cells, CD56 expression on T cells is not constitutive. It has been observed that 
CD56+ T cells are almost absent at birth and in adults are found as oligoclonal 
A B 
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expansions [104], suggesting a link between CD56 expression and number of division 
cycles.  
PHA-induced down-modulation of CD56 expression by CD8+ T cells was not a 
lasting effect. It took place during the first four weeks in the large majority of samples 
studied but differed thereafter. In three long-term cultures, and from day 28 onwards, 
cultures began to diverge with one sample keeping the up-down pattern until week nine, 
and two other samples displaying a gradual increase in CD8+CD56+ T cells. This was 
most striking in one culture, where after day 42 the CD8+CD56+ T lymphocytes reached 
a plateau-like phase, showing an impressive percentage of CD56 of around 50%. Thus, 
these two cell cultures apparently became “refractory” to the purported PHA-signaling 
interference with the IL-15 pathway. One possible mechanism rendering these CD8+ T 
cells refractory is the possible “constitutive” expression of CD56 due to a complete 
demethylation of the gene promoter, as referred above [156]. Whether this is the result 
of the “replicative past” of the CD8+ T cells under study, remains to be ascertained.  
 Finally, we were also able to show a positive correlation between size (FS) and 
complexity/granularity (SS), and the time of cell culture under our culture conditions. 
This may be a consequence of the combined use of IL-15/PHA on cell proliferation, 
resulting in a progeny of blastoid/activated cells [12, 50, 153, 157-162]. The observed 
increase in SS along the culture time imply an increase on CD8+ T cell granularity, 
indicating that long-term IL-15/PHA cultured CD8+ T cells are functional CD8+ T cells 
displaying an increased cytotoxic potential, as determined by high granzyme B/perforin 
content [12, 95]. Due to their features, IL-15/PHA cultured CD8+ T cells can be 
considered large granular lymphocytes endowed with cytolitic activity and capable to 
secrete and array of regulatory cytokines, as described by us [95, 104]. Interestingly, 
CD8+ T cells with these characteristics are being used in vivo both in animals and in 
humans for the treatment of melanoma, renal cell carcinoma, non-Hodgkin’s 
lymphoma, and lung and colorectal cancers [163, 164]. Last, but not least, the 
morphological characteristics of our in vitro CD8+CD56+ T cells are reminiscent of the 
large granular lymphocytes described in leukemic patients. Indeed, IL-15 has been 
proposed to play a role in the development of T cell large granular lymphocyte (T-LGL) 
leukemia [165], an indolent lymphoproliferative disorder that represents a highly 
significant clonal expansion of cytotoxic T cells [166-168]. There are several evidences 
that aggressive variants of human T-cell large granular lymphocyte leukemia are 
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characterized by an immunophenotype that includes surface expression of CD56, along 
with a variable surface expression pattern of NK cell and/or T cell markers [166, 169-
171].  
 
5.3. Future prospects 
In the present investigation we were able to maintain CD8+ T lymphocytes in 
culture with IL-15/PHA for long periods of time. Moreover, during this period these 
cells acquired a large granular morphology and increased the expression of a prototypic 
marker of NKT cells (CD56), suggesting a process of cellular differentiation induced by 
IL-15. The successful establishment of these long-term cultures is the starting point to 
set up a solid cell culture method, scientifically accurate, to study the effects of IL-15 on 
the upregulation of other NKR for long periods of time. 
 
The observed downmodulation of CD56 expression after PHA addition to cell 
cultures remains to be experimentally substantiated, and more work needs to be done to 
unravel the reason behind the PHA interference on CD56+ T cells percentage. In fact, it 
would be interesting to validate or exclude our hypotheses. Both the signaling pathways 
through IL-15 receptor and the TCR complex deliver significantly overlapping 
downstream signals in memory phenotype CD8+ T cells in vitro, which could actually 
be an interesting pathway to uncover, since it remains to be determined at what level 
these two signals converge, and what molecules are involved in the overlapping 
processes. Furthermore, it would be interesting to perform similar experiments but 
replacing TCR triggering with anti-CD3 stimulation instead of PHA, which would 
provide more information to assess if the downmodulation of CD56 expression is 
indeed related with intracellular cascade ligands competition. Alternatively, the 
decrease on CD56 expression could be explained by enhanced apoptosis after PHA 
addition, which in the future could be experimentally assessed.  
 
As already discussed, a possible reason explaining the expression of CD56 on 
dividing blasts, could be an epigenetic mechanism, such as modulation of the 
methylation status of the transcriptional active region, taking place during development 
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and cell proliferation [155]. Hence, it would be interesting to experimentally uncover if 
the apparent evasion on the effect of PHA downmodulating CD56 expression is 
justified by demethylation, rendering the CD56 gene to be expressed constitutively.  
 
Finally, inadequate expression of cytokines and/or abnormal activation of 
cytokine receptors have been suggested to complement genetic aberrations in 
leukemogenesis, thus, supporting survival and proliferation of leukemic cells [172, 
173]. In this context, IL-15 may have a role in the development of T cell large granular 
leukemias (T-LGL) [165]. Therefore, our in vitro model might allow to determine 
whether IL-15 is a leukemogenic factor capable of T-cell leukemic transformation, and 
to unveil the molecular mechanisms underlining this process. 
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VI. Conclusions 
In the present investigation we were able to maintain CD8+ T lymphocytes in 
culture for long periods of time (over two months), when maintained in the continuous 
alternate presence of IL-15 and PHA, respectively. During this period, CD8+ T cells 
acquired a large granular morphology and expressed CD56, the prototypic marker of 
NKT cells. Overall, the data suggest that the combination of TCR-independent (IL-15) 
and TCR-dependent (PHA) signals keeps CD8+ T cells into a continuous differentiation 
process.  
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